Who may be eligible You may be a candidate if youre an adult who: Has BMI 30 , or BMI 27 with a weight-related condition (e.g., prediabetes, type 2 diabetes, high blood pressure, high cholesterol, sleep apnea)
High levels of visceral fat are linked to increased risk of: Heart disease Type 2 Diabetes Metabolic syndrome Reducing visceral fat is one of the most important health benefits of medically supervised weight loss
Glycine can also improve cognition through anti-excitatory effects, [31-33] and stimulation of the N-methyl-D-aspartate (NMDA) receptors , [34,35] which supports a process called long-term potentiation (LTP)
Popular GLP-1 medications used to treat type 2 diabetes and obesitysemaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound)may be linked to a small increase in the risk of a rare eye condition that can cause sudden vision loss, according to new research
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
National Science & Technology Major Project of ChinaKey New Drug Creation and Manufacturing Program 2018ZX09735001 (M.-W.W.) and 2018ZX09711002002005 (D.Y)
